stockrowIovance Biotherapeutics, Inc.
IOVA Healthcare Biotechnology
Iovance Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $263.5 million, up 60.6% from fiscal 2024.
- Revenue
- +80.1%
- EPS
- +80.0%
- Free cash flow
- +89.7%
Quarter to September 2026, against a year earlier
Follow IOVA
Alert me
Iovance Biotherapeutics, Inc. (IOVA) EPS (diluted)
Iovance Biotherapeutics, Inc.'s EPS (diluted) for fiscal 2025 was −$1.09, compared with −$1.28 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$0.53. Over the past ten years it has ranged from −$2.49 (fiscal 2022) to −$0.62 (fiscal 2015); the current reading is higher than 91% of that period. EPS (diluted) has risen for 3 consecutive fiscal years. Iovance Biotherapeutics, Inc. ranks 135th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$1.09 | — |
| FY2024 | −$1.28 | — |
| FY2023 | −$1.89 | — |
| FY2022 | −$2.49 | — |
| FY2021 | −$2.23 | — |
| FY2020 | −$1.88 | — |
| FY2019 | −$1.59 | — |
| FY2018 | −$1.27 | — |
| FY2017 | −$1.41 | — |
| FY2016 | −$1.85 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | −$0.05 | — |
| Jun 2026 | −$0.11 | — |
| Mar 2026 | −$0.19 | — |
| Dec 2025 | −$0.18 | — |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $2.11 |
| IOVA Iovance Biotherapeutics, Inc. | −$0.53 |
| ABCL AbCellera Biologics Inc. compare | −$0.54 |
| TNGX Tango Therapeutics, Inc. compare | −$0.85 |
| RLAY Relay Therapeutics, Inc. compare | −$1.57 |
| EWTX Edgewise Therapeutics, Inc. compare | −$1.85 |
| XENE Xenon Pharmaceuticals Inc. compare | −$4.74 |
| IRON Disc Medicine, Inc. compare | −$6.58 |
| PBLS Parabilis Medicines, Inc. compare | −$83.02 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on IOVA
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- The full statement